Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Asian Journal of Andrology ; (6): 179-183, 2023.
Article in English | WPRIM (Western Pacific) | ID: wpr-971024

ABSTRACT

Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of genomic characteristics with efficacy outcomes. We conducted a retrospective real-world study of 25 mCRPC patients who received PD-1 inhibitor plus anlotinib after the progression to standard treatments. The clinical information was extracted from the electronic medical records and 22 patients had targeted circulating tumor DNA (ctDNA) next-generation sequencing. Statistical analysis showed that 6 (24.0%) patients experienced prostate-specific antigen (PSA) response and 11 (44.0%) patients experienced PSA reduction. The relationship between ctDNA findings and outcomes was also analyzed. DNA-damage repair (DDR) pathways and homologous recombination repair (HRR) pathway defects indicated a comparatively longer PSA-progression-free survival (PSA-PFS; 2.5 months vs 1.2 months, P = 0.027; 3.3 months vs 1.2 months, P = 0.017; respectively). This study introduces the PD-1 inhibitor plus anlotinib as a late-line therapeutic strategy for terminal mCRPC. PD-1 inhibitor plus anlotinib may be a new treatment choice for terminal mCRPC patients with DDR or HRR pathway defects and requires further investigation.


Subject(s)
Male , Humans , Prostate-Specific Antigen , Treatment Outcome , Prostatic Neoplasms, Castration-Resistant/drug therapy , Immune Checkpoint Inhibitors/therapeutic use , Retrospective Studies
2.
Chinese Journal of Stomatology ; (12): 347-351, 2008.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-235904

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the effect of putative periodontopathogenic bacteria on the development of drug-induced gingival overgrowth (GO) in renal transplant recipients.</p><p><b>METHODS</b>A total of 57 patients undergoing cyclosporine treatment were divided into two groups according to GO index: with gingival overgrowth (group A) and without gingival overgrowth (group B). Demographic, pharmacologic and periodontal data were analyzed. The real-time polymerase chain reaction (PCR) method was used to detect and quantify five putative periodontopathogenic bacteria, including Porphyromonas gingivalis (Pg), Actinobacillus actinomycetemcomitans (Aa), Prevotella intermedia (Pi), Treponema denticola (Td) and Tannerella forsythia (Tf) in subgingival samples. Moreover, the relationship between the bacterial amount and the severity of GO was analyzed.</p><p><b>RESULTS</b>Group A presented a significantly higher plaque index, sulcus bleeding index and probing depth than group B (P < 0.01). The occurrences of Pg, Td, and Tf in the group A (96%, 82% and 89%) were significantly increased compared with those in the group B (69%, 55% and 66%, P < 0. 05), respectively. The prevalence of Pg, Td, and Tf in the group A (79%) was markedly higher than that in the group B (38%, P < 0.01). The bacterial amount of Pg, Td, Tf and Pi were enhanced along with the severity of GO. However, the bacterial amount of Aa had no difference between two groups.</p><p><b>CONCLUSIONS</b>Pg, Td, and Tf may have a significant relationship with the development of GO.</p>


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Aggregatibacter actinomycetemcomitans , Bacterial Typing Techniques , Cyclosporine , DNA, Bacterial , Gingival Overgrowth , Microbiology , Kidney Transplantation , Polymerase Chain Reaction , Methods , Porphyromonas gingivalis , Prevotella intermedia , Treponema denticola
SELECTION OF CITATIONS
SEARCH DETAIL
...